Chronic lymphocytic leukemia is an incurable leukemia and the most common hematological malignancy in Manitoba. As the population ages, the incidence of CLL will increase. How we can improve survival of CLL patients and better manage their care requires a collaborative effort where evidence-based research will play a major role. CCMB and the University of Manitoba provide a unique opportunity for us to implement a research cluster to tackle this challenge. We will use existing provincial network to share important clinical findings about screening for second cancers, comorbidities, and referring patients to the CCMB CLL clinic.
Over the last 10 years, the highly productive collaborations between Drs. Gibson, Johnston, Banerji and Marshall continues the legacy of outstanding hematology research in Manitoba. The Cluster aims to bring together researchers, government decision makers, patients, primary care providers and cancer specialists to improve the survival of CLL patients and improve their quality of life in a cost-effective manner. It intends to create new technologies, new approaches to targeted therapy and better understanding of the complex relationship between managing CLL concurrently with other diseases. Looking forward, these results will have an impact on pharmaceutical and diagnostic industries. The Cluster establishes Manitoba as a centre of academic and clinical excellence in CLL.